Effects of irradiated tumor vaccine and continuous localized infusion of granulocyte-macrophage colony-stimulating factor on neuroblastomas in mice

Journal of Pediatric Surgery

Volumn 37, Issue 9, 2002, Pages 1298-1304

  Chen, Yun ^a   Lin, Swei Ming ^a   Lai, Hong Shiee ^a   Tseng, Sheng Hong ^a   Chen, Wei Jao ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Granulocyte macrophage colony stimulating factor; Immunotherapy; Neuroblastoma; Tumor vaccine

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; HISTOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INJECTION SITE; IRRADIATION; LYMPHOCYTIC INFILTRATION; MOUSE; NEUROBLASTOMA; NONHUMAN; OSMOTIC MINIPUMP; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR REGRESSION;

EID: 0036725735     PISSN: 00223468     EISSN: None     Source Type: Journal    
DOI: 10.1053/jpsu.2002.34995     Document Type: Article

References (37)

1. Antitumor vaccine effect of irradiated murine neuroblastoma cells producing interleukin-2 or granulocyte macrophage-colony stimulating factor
2. Neuroblastoma regression and immunity induced by transgenic expression of interleukin-12
3. High-dose chemotherapy supported by marrow infusions for advanced neuroblastoma: A Pediatric Oncology Group Study
4. How frequent is spontaneous remission of neuroblastomas? Implications for screening
5. Do infants with IV-S neuroblastoma need treatment?
6. Immunotherapy: Neuroblastoma as a model
7. Mechanisms of selective killing of neuroblastoma cells by natural killer cells and lymphokine activated killer cells: Potential for residual disease eradication
8. Effective immunization against neuroblastoma using double-transduced tumor cells secreting GM-CSF and interferon-γ
9. Interleukin-2 gene-modified allogenic tumor cells for treatment of relapsed neuroblastoma
10. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune response in patients with neuroblastoma
11. DNA vaccination with HuD inhibits growth of a neuroblastoma in mice
12. D2 antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age
13. 3F8 monoclonal antibody treatment of patients with stage 4 neuroblastoma: A phase II study
14. Combined preoperative and postoperative immunotherapy for murine C 1300 neuroblastoma
15. Neuroblastoma cells expressing mature IL-18, but not proIL-18, induce a strong and immediate antitumor immune response
16. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma
17. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy
18. Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12
19. Induction of antitumor immunity with Fas/APO-1 ligand (CD95L)-transfected neuroblastoma neuro-2a cells
20. Impaired tumorigenicity and decreased liver metastasis of murine neuroblastoma cells engineered to secrete interleukin-2 or granumocyte macrophage colony-stimulating factor
21. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression
22. Modulation of immune function by glioma
23. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo
24. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific and long-term anti-tumor immunity
25. Granulocyte-macrophage colony-stimulating factor and B7-2 combination immunogene therapy in an allogenic Hu-PBL-SCID/beige mouse-human glioblastoma multiforme model
26. Demonstration of a rational strategy for human prostate cancer gene therapy
27. Evidence that granulocyte macrophage-colony-stimulating factor regulates the distribution and differentiated state of dendritic cells/Langerhans cells in human lung and lung cancers
28. Regression of orthotopic brain tumors by cytokine-assisted tumor vaccines primed in the brain
29. Induction of antitumor immunity by intracerebrally implanted rat C6 glioma cells genetically engineered to secrete cytokines
30. Paracrine cytokine adjuvants in cancer immunotherapy
31. Understanding the dendritic cell lineage through a study of cytokine receptors
32. Immortalized dendritic cell line fully competent in antigen presentation initiates primary T cell responses in vivo
33. The 9L rat brain tumor: Description and application of an animal model
34. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor
35. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity
36. Role of bonemarrow-derived cells in presenting MHC class I-restricted tumor antigens